Reliability of Sequential Naloxone Challenge Tests

References

• Marshall I., Weinstock M. Quantitative method for assessing one symptom of the withdrawal syndrome in mice after chronic morphine administration. Nature (London) 1971; 234: 223–224
   Google Scholar
• Jasinski D. R. Assessment of the abuse potentiality of morphinelike drugs (methods used in man). Drug Addiction I, W. R. Martin. Springer-Verlag, Berlin 1977
   Google Scholar
• Kosten T. A., Jacobsen L. K., Kosten T. R. Severity of precipitated opiate withdrawal predicts drug dependence by DSM-III-R criteria. Am. J. Drug Alcohol Abuse 1989; 15: 237–250
   PubMed Web of Science ®Google Scholar
• Zilm D. H., Sellers E. M. The quantitative assessment of physical dependence on opiates. Drug Alcohol Depend 1978; 3: 419–428
   PubMed Web of Science ®Google Scholar
• Wang R. I., Kochar C, Hasegawa A. T., et al. Initial methadone dose in treating opiate addiction. Int. J. Addict. 1982; 17(2)357–363
   PubMed Web of Science ®Google Scholar
• Kanof P. D., Aronson M. J., Ness R., et al. Levels of opioid physical dependence in heroin addicts. Drug Alcohol Depend 1991; 27: 253–363
   Google Scholar
• Handelsman L., Cochrane K. J., Aronson M. J., et al. Two new rating scales for opiate withdrawal. Am. J. Drug Alcohol Abuse 1987; 13: 293–308
   PubMed Web of Science ®Google Scholar
• Preston K. L., Bigelow G. E., Liebson I. A. Butorphanol-precipitated withdrawal in opiate-dependent human volunteers. J. Pharmacol. Exp. Ther. 1988; 246(2)441–448
   PubMed Web of Science ®Google Scholar
• Strain E. C, Preston K. L., Liebson I. A., et al. Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers. J. Pharmacol. Exp. Ther. 1992; 261(3)985–993
   PubMed Web of Science ®Google Scholar
• Preston K. L., Bigelow G. E., Liebson I. A. Antagonist effects of nalbuphine in opioid-dependent human volunteers. J. Pharmacol. Exp. Ther. 1989; 248(3)929–937
   PubMed Web of Science ®Google Scholar
• Rosen M. I., Oliveros S. A., Wallace E. A., et al. Nimodipine Effects on Opiate Withdrawal. American College of Neuropsychopharmacology Abstract presented. Puerto Rico December, 1992
   Google Scholar
• Kosten T. R., Morgan C, Kreek M. J. Beta endorphin levels during heroin, methadone, buprenorphine, and naloxone challenges: Preliminary findings. Biol. Psychiatry 1992; 32: 523–528
   Web of Science ®Google Scholar
• Clement-Jones V., McLoughlin L., Lowry P. J., et al. Acupuncture in heroin addicts: Changes in met-enkephalin and beta-endorphin in blood and cerebrospinal fluid. Lancet 1979; 11: 380–383
   Google Scholar
• Emrich H. M., Nusselt L., Granisch C, et al. Heroin addiction: Beta endorphin in immunoreactivity in plasma increases during withdrawal. Pharmacopsychiatry 1983; 16: 93–96
   Google Scholar
• Volavka J., Cho D., Mallya A. Naloxone increases ACTH and Cortisol levels in man. New Engl. J. Med. 1979; 300(18)1056–1057
   PubMed Web of Science ®Google Scholar
• Naber D., Pickar D., Davis G. C, et al. Naloxone effects on beta-endorphin, Cortisol, prolactin, growth hormone, HVA, MHPG in plasma of normal volunteers. Psychop-harmacology 1981; 74: 125–128
   Google Scholar
• Kreek M. J., Schneider B. S., Raghunath J., et al. Prolonged (24 hour) infusion of the opioid antagonist naloxone does not significantly alter plasma levels of Cortisol and ACTH in humans. Abstracts of the Seventh International Congress of Endocrinology. Excerpta Medica, Amsterdam 1984; 845, (International Congress Series 652)
   Google Scholar
• Peachey J. E., Lei H. Assessment of opioid dependence with naloxone. Br. J Addict. 1988; 83: 193–201
   PubMedGoogle Scholar
• Bartko J. J. The intraclass correlation coefficient as a measure of reliability. Psychol. Rep. 1966; 19: 3–11
   PubMed Web of Science ®Google Scholar
• Shrout P. E., Fleiss J. L. Intraclass correlations: Uses in assessing rater reliability. Psychol. Bull. 1979; 86: 420–428
   PubMed Web of Science ®Google Scholar
• Matthews J. N. S., Douglas G. A., Campbell M. J., et al. Analysis of serial measurements in medical research. Br. Med. J. 1990; 300: 230–235
   PubMed Web of Science ®Google Scholar
• O'Brien C, Greenstein R. Naltrexone in a behavioral treatment program. Narcotic Antagonists: Naltrexone, D. Julius, P. Renault. US Government Printing Office, Washington, DC 1976; 136–140, [NIDA Research Monograph, No. 9, DHEW Publication No. (ADM) 77-387)
   Google Scholar
• O'Brien C. P., Ng L. K. Y. Innovative treatments for drug addiction. Handbook of Drug Abuse, R. I. DuPont, A. Goldstein, J. O'Donnell. US Government Printing Office, Washington, DC 1979; 193–202
   Google Scholar
• Kosten T. R., Kreek M. J., Ragunath J., et al. A preliminary study of beta-endorphin during chronic naltrexone maintenance treatment in ex-opiate addicts. Life Sci 1986; 39: 55–59
   Google Scholar
• Bloom L. J., Houston B. K., Burish T. G. An evaluation of finger pulse volume as a psychophysiological measure of anxiety. Psychophysiology 1976; 13: 40–42
   Google Scholar
• Charney D. S., Riordan C. E., Kleber H. D., et al. Clonidine and naltrexone: A safe, effective, and rapid treatment of abrupt withdrawal from methadone therapy. Arch. Gen Psychiatry 1982; 39: 1327–1332
   PubMed Web of Science ®Google Scholar
• Loimer N., Schmid R., Lenz K., et al. Acute blocking of naloxone-precipitated opiate withdrawal symptoms by methohexitone. Br. J. Psychiatry 1990; 157: 748–752
   PubMed Web of Science ®Google Scholar
• Krystal J. H., Walker M. W., Heninger G. R. Intermittent naloxone attenuates the development of physical dependence on methadone in rhesus monkeys. Eur. J. Pharmacol. 1989; 160: 331–338
   PubMed Web of Science ®Google Scholar
• Jasinski D. R., Johnson R. E., Koeher T. R. Clonidine in morphine withdrawal: Differential effects on signs and symptoms. Arch. Gen. Psychiatry 1985; 42(11)1063–1066
   PubMed Web of Science ®Google Scholar